T-cadherin gene variants are associated with type 2 diabetes and the Fatty Liver Index in the French population

Diabetes and Metabolism

Volumn 43, Issue 1, 2017, Pages 33-39

  Nicolas, A ^a,b,c   Aubert, R ^a   Bellili Munoz N ^a   Balkau, B ^d   Bonnet, F ^d,e   Tichet, J ^f   Velho, G ^a   Marre, M ^a,c,g   Roussel, R ^a,b,c,g   Fumeron, F ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSERM   (France)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f IRSA   (France)

^g BICHAT HOSPITAL   (France)

Author keywords

Adiponectin; Body mass index; Fatty Liver Index; Genetic polymorphisms; T cadherin; Type 2 diabetes

Indexed keywords

ADIPONECTIN; CADHERIN; HEMOGLOBIN A1C; T CADHERIN; UNCLASSIFIED DRUG; H-CADHERIN;

ADULT; AGED; ARTICLE; BODY MASS; CAUCASIAN; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE MARKER; FATTY LIVER; FATTY LIVER INDEX; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; DIABETES MELLITUS, TYPE 2; FRANCE; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MIDDLE AGED;

ADIPONECTIN; ADULT; AGED; CADHERINS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; FRANCE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84973499989     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2016.05.005     Document Type: Article

References (37)

1. [1] Fumeron, F., Aubert, R., Siddiq, A., Betoulle, D., Péan, F., Hadjadj, S., et al. Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period the epidemiologic data on the insulin resistance syndrome prospective study. Diabetes 53 (2004), 1150–1157.
2. [2] Jaziri, R., Aubert, R., Roussel, R., Emery, N., Maimaitiming, S., Bellili, N., et al. Association of ADIPOQ genetic variants and plasma adiponectin isoforms with the risk of incident renal events in type 2 diabetes. Nephrol Dial Transplant 25 (2010), 2231–2237, 10.1093/ndt/gfp771.
3. [3] Polyzos, S.A., Toulis, K.A., Goulis, D.G., Zavos, C., Kountouras, J., Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 60 (2011), 313–326, 10.1016/j.metabol.2010.09.003.
4. [4] Polyzos, S.A., Kountouras, J., Zavos, C., Tsiaousi, E., The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 12 (2010), 365–383, 10.1111/j.1463-1326.2009.01176.x.
5. [5] Hug, C., Wang, J., Ahmad, N.S., Bogan, J.S., Tsao, T.-S., Lodish, H.F., T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A 101 (2004), 10308–10313, 10.1073/pnas.0403382101.
6. [6] Philippova, M., Joshi, M.B., Kyriakakis, E., Pfaff, D., Erne, P., Resink, T.J., A guide and guard: the many faces of T-cadherin. Cell Signal 21 (2009), 1035–1044.
7. [7] Denzel, M.S., Scimia, M.-C., Zumstein, P.M., Walsh, K., Ruiz-Lozano, P., Ranscht, B., T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 120 (2010), 4342–4352, 10.1172/JCI43464.
8. [8] Tyrberg, B., Miles, P., Azizian, K.T., Denzel, M.S., Nieves, M.L., Monosov, E.Z., et al. T-cadherin (Cdh13) in association with pancreatic β-cell granules contributes to second phase insulin secretion. Islets 3 (2011), 327–337, 10.4161/isl.3.6.17705.
9. [9] Dastani, Z., Hivert, M.-F., Timpson, N., Perry, J.R.B., Yuan, X., Scott, R.A., et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet, 8, 2012, e1002607, 10.1371/journal.pgen.1002607.
10. [10] Jee, S.H., Sull, J.W., Lee, J.-E., Shin, C., Park, J., Kimm, H., et al. Adiponectin concentrations: a genome-wide association study. Am J Hum Genet 87 (2010), 545–552, 10.1016/j.ajhg.2010.09.004.
11. [11] Fava, C., Danese, E., Montagnana, M., Sjögren, M., Almgren, P., Guidi, G.C., et al. A variant upstream of the CDH13 adiponectin receptor gene and metabolic syndrome in Swedes. Am J Cardiol 108 (2011), 1432–1437, 10.1016/j.amjcard.2011.06.068.
12. [12] Org, E., Eyheramendy, S., Juhanson, P., Gieger, C., Lichtner, P., Klopp, N., et al. Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations. Hum Mol Genet 18 (2009), 2288–2296, 10.1093/hmg/ddp135.
13. [13] Chung, C.-M., Lin, T.-H., Chen, J.-W., Leu, H.-B., Yang, H.-C., Ho, H.-Y., et al. A genome-wide association study reveals a quantitative trait locus of adiponectin on CDH13 that predicts cardiometabolic outcomes. Diabetes 60 (2011), 2417–2423, 10.2337/db10-1321.
14. [14] Balkau, B., Lange, C., Vol, S., Fumeron, F., Bonnet, F., Group Study D.E.S.I.R. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol, 10, 2010, 56, 10.1186/1471-230X-10-56.
15. [15] Fumeron, F., Lamri, A., Abi Khalil, C., Jaziri, R., Porchay-Baldérelli, I., Lantieri, O., et al. Dairy consumption and the incidence of hyperglycemia and the metabolic syndrome: results from a French prospective study. Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 34 (2011), 813–817, 10.2337/dc10-1772.
16. [16] Marre, M., Lievre, M., Chatellier, G., Mann, J.F.E., Passa, P., Ménard, J., et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ, 328, 2004, 495, 10.1136/bmj.37970.629537.0D.
17. [17] Lièvre, M., Marre, M., Chatellier, G., Plouin, P., Réglier, J., Richardson, L., et al. The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group. Control Clin Trials 21 (2000), 383–396.
18. [18] Bonnet, F., Balkau, B., Malécot, J.M., Picard, P., Lange, C., Fumeron, F., et al. Sex hormone-binding globulin predicts the incidence of hyperglycemia in women: interactions with adiponectin levels. Eur J Endocrinol Eur Fed Endocr Soc 161 (2009), 81–85, 10.1530/EJE-09-0202.
19. [19] Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol, 6, 2006, 33, 10.1186/1471-230X-6-33.
20. [20] Wu, Y., Gao, H., Li, H., Tabara, Y., Nakatochi, M., Chiu, Y.-F., et al. A meta-analysis of genome-wide association studies for adiponectin levels in East Asians identifies a novel locus near WDR11-FGFR2. Hum Mol Genet 23 (2014), 1108–1119, 10.1093/hmg/ddt488.
21. [21] Morisaki, H., Yamanaka, I., Iwai, N., Miyamoto, Y., Kokubo, Y., Okamura, T., et al. CDH13 gene coding T-cadherin influences variations in plasma adiponectin levels in the Japanese population. Hum Mutat 33 (2012), 402–410, 10.1002/humu.21652.
22. [22] Nyholt, D.R., A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 74 (2004), 765–769.
23. [23] Kitamoto, A., Kitamoto, T., Nakamura, T., Matsuo, T., Nakata, Y., Hyogo, H., et al. CDH13 polymorphisms are associated with adiponectin levels and metabolic syndrome traits independently of visceral fat mass. J Atheroscler Thromb, 2015, 10.5551/jat.31567.
24. [24] Gao, H., Kim, Y.-M., Chen, P., Igase, M., Kawamoto, R., Kim, M.K., et al. Genetic variation in CDH13 is associated with lower plasma adiponectin levels but greater adiponectin sensitivity in East Asian populations. Diabetes 62 (2013), 4277–4283, 10.2337/db13-0129.
25. [25] Yadav, A., Kataria, M.A., Saini, V., Yadav, A., Role of leptin and adiponectin in insulin resistance. Clin Chim Acta Int J Clin Chem 417 (2013), 80–84, 10.1016/j.cca.2012.12.007.
26. [26] Tishinsky, J.M., Robinson, L.E., Dyck, D.J., Insulin-sensitizing properties of adiponectin. Biochimie 94 (2012), 2131–2136, 10.1016/j.biochi.2012.01.017.
27. [27] Shehzad, A., Iqbal, W., Shehzad, O., Lee, Y.S., Adiponectin: regulation of its production and its role in human diseases. Horm Athens Greece 11 (2012), 8–20.
28. [28] Lindsay, R.S., Funahashi, T., Hanson, R.L., Matsuzawa, Y., Tanaka, S., Tataranni, P.A., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360 (2002), 57–58, 10.1016/S0140-6736(02)09335-2.
29. [29] Otsuka, I., Watanabe, Y., Hishimoto, A., Boku, S., Mouri, K., Shiroiwa, K., et al. Association analysis of the Cadherin13 gene with schizophrenia in the Japanese population. Neuropsychiatr Dis Treat 11 (2015), 1381–1393, 10.2147/NDT.S84736.
30. [30] Putku, M., Kals, M., Inno, R., Kasela, S., Org, E., Kožich, V., et al. CDH13 promoter SNPs with pleiotropic effect on cardiometabolic parameters represent methylation QTLs. Hum Genet 134 (2015), 291–303, 10.1007/s00439-014-1521-6.
31. [31] Chan, D.W., Lee, J.M.F., Chan, P.C.Y., Ng, I.O.L., Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells. Int J Cancer 123 (2008), 1043–1052, 10.1002/ijc.23634.
32. [32] Jung, T.W., Lee, Y.J., Lee, M.W., Kim, S.M., Jung, T.W., Full-length adiponectin protects hepatocytes from palmitate-induced apoptosis via inhibition of c-Jun NH2 terminal kinase. FEBS J 276 (2009), 2278–2284, 10.1111/j.1742-4658.2009.06955.x.
33. [33] Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2015 n.d. doi:10.1016/j.metabol.2015.11.006.
34. [34] Grønbaek, H., Thomsen, K.L., Rungby, J., Schmitz, O., Vilstrup, H., Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. Expert Rev Gastroenterol Hepatol 2 (2008), 705–711, 10.1586/17474124.2.5.705.
35. [35] Promrat, K., Longato, L., Wands, J.R., de la Monte, S.M., Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels. Hepatol Res 41 (2011), 754–762, 10.1111/j.1872-034X.2011.00815.x.
36. [36] Holland, W.L., Miller, R.A., Wang, Z.V., Sun, K., Barth, B.M., Bui, H.H., et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17 (2011), 55–63, 10.1038/nm.2277.
37. [37] Locke, A.E., Kahali, B., Berndt, S.I., Justice, A.E., Pers, T.H., Day, F.R., et al. Genetic studies of body mass index yield new insights for obesity biology. Nature 518 (2015), 197–206, 10.1038/nature14177.